Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer

por Inokuchi, M, Yamashita, T, Yamada, H, Kojima, K, Ichikawa, W, Nihei, Z, Kawano, T, Sugihara, K
Publicado 2006

Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer

por Ichikawa, W, Takahashi, T, Suto, K, Yamashita, T, Nihei, Z, Shirota, Y, Shimizu, M, Sasaki, Y, Hirayama, R
Publicado 2004

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for meta...

por Ichikawa, W, Uetake, H, Shirota, Y, Yamada, H, Takahashi, T, Nihei, Z, Sugihara, K, Sasaki, Y, Hirayama, R
Publicado 2003

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials

por Sebio, A., Stintzing, S., Heinemann, V., Sunakawa, Y., Zhang, W., Ichikawa, W., Tsuji, A., Takahashi, T., Parek, A., Yang, D., Cao, S., Ning, Y., Stremitzer, S., Matsusaka, S., Okazaki, S., Barzi, A., Berger, M., Lenz, H-J
Publicado 2016

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer

por Matsuyama, Masato, Ishii, H., Furuse, J., Ohkawa, S., Maguchi, H., Mizuno, N., Yamaguchi, T., Ioka, T., Ajiki, T., Ikeda, M., Hakamada, K., Yamamoto, M., Yamaue, H., Eguchi, K., Ichikawa, W., Miyazaki, M., Ohashi, Y., Sasaki, Y.
Publicado 2014

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients

por Ichikawa, W, Uehara, K, Minamimura, K, Tanaka, C, Takii, Y, Miyauchi, H, Sadahiro, S, Fujita, K, Moriwaki, T, Nakamura, M, Takahashi, T, Tsuji, A, Shinozaki, K, Morita, S, Ando, Y, Okutani, Y, Sugihara, M, Sugiyama, T, Ohashi, Y, Sakata, Y
Publicado 2015

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

por Yasui, H., Okita, Y., Nakamura, M., Sagawa, T., Watanabe, T., Kataoka, K., Manaka, D., Shiraishi, K., Akazawa, N., Okuno, T., Shimura, T., Shiozawa, M., Sunakawa, Y., Ota, H., Kotaka, M., Okuyama, H., Takeuchi, M., Ichikawa, W., Fujii, M., Tsuji, A.
Publicado 2023

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)

por Sunakawa, Y., Satake, H., Usher, J., Jaimes, Y., Miyamoto, Y., Nakamura, M., Kataoka, M., Shiozawa, M., Takagane, A., Terazawa, T., Watanabe, T., Ishiguro, K., Tanaka, C., Takeuchi, M., Fujii, M., Danenberg, K., Danenberg, P.V., Lenz, H.-J., Sekikawa, T., Ichikawa, W.
Publicado 2022